Sequencing Patterns and Treatment Effectiveness in ALK-positive aNSCLC Following First-Line Alectinib or Brigatinib

The National Comprehensive Cancer Network guidelines recommend alectinib, brigatinib (second-generation) or lorlatinib (third-generation) anaplastic lymphoma kinase (ALK) inhibitors (ALKis) as the preferred first-line treatment for ALK-positive advanced non-small-cell lung cancer (aNSCLC). Second-line recommended treatments are lorlatinib or chemotherapy. There is limited data describing contemporary real-world treatment patterns of next-generation ALKis. This study aims to describe sequencing patterns and treatment effectiveness of first- and second-line treatments in patients with ALK-positive aNSCLC initiating first-line second-generation ALKi in routine clinical practices in the US.